Table of Contents
The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a requirement referred to as the ‘cold chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection
What You Will Learn
• Provides detailed analysis of lyophilized drugs, as-supplied packaging and therapeutic indication
• Analyzes therapeutic demand drivers and evaluates lyophilized drugs in eleven therapeutic areas
• Analyzes lyophilization technologies and market development issues
• Provides market data and forecasts to 2020
• Profiles market participants, their product development activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of technology and regulatory factors on commercialization and market access
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
North America Facial Injectables Market: Overview This report on the North America facial injectables market analyzes the current and future prospects of the market. The report comprises an elaborate executive ...
Global Pulmonary Drug Delivery Devices Market: Overview This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report ...
The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period. The increase ...